Nevakar Injectables patents expiration
1. Norepinephrine Bitartrate In 0.9% Sodium Chloride patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11413259 | NEVAKAR INJECTABLES | Norepinephrine compositions and methods therefor |
Jan, 2038
(14 years from now) | |
| US10420735 | NEVAKAR INJECTABLES | Norepinephrine compositions and methods therefor |
Jan, 2038
(14 years from now) | |
| US10226436 | NEVAKAR INJECTABLES | Norepinephrine compositions and methods therefor |
Jan, 2038
(14 years from now) | |
| US10159657 | NEVAKAR INJECTABLES | Norepinephrine compositions and methods therefor |
Jan, 2038
(14 years from now) | |
| US10568850 | NEVAKAR INJECTABLES | Norepinephrine compositions and methods therefor |
Jan, 2038
(14 years from now) | |
| US11602508 | NEVAKAR INJECTABLES | Norepinephrine compositions and methods therefor |
Jan, 2038
(14 years from now) | |
Drugs and Companies using NOREPINEPHRINE BITARTRATE ingredient
Market Authorisation Date: 06 October, 2022
Treatment: Indicated to raise blood pressure in adult patients with severe, acute hypotension
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic